Now PlayingEP. 1 Patient vs Provider Perceptions: Expert Opinions on Addressing the Emotional Impact of Vitiligo
EP. 2 Vitiligo in a 35-Year-Old Female: Case-Based Discussion, Treatment Sequencing, and Practical Insights
EP. 3 Vitiligo Case-Based Discussion: Impact of Stigma, Social Perception, and Practical Management Strategies
EP. 4 Topical Ruxolitinib in Vitiligo: Efficacy, Regional Approvals, and Treatment Strategies in African American Patients
Noninvasive Imaging Maps Repigmentation and Melanocyte Activation in Ruxolitinib-Treated VitiligoByMarie Bosslett, Assistant EditorAugust 24th 2026
Meta-Analysis Finds Significantly Lower SCC Risk in Patients With VitiligoByMarie Bosslett, Assistant EditorAugust 20th 2026
How to Explain JAK Inhibitor Safety to PatientsByLisa Swanson, MD, FAAD,Shannon Heaning, Content AssociateJuly 31st 2026
Ritlecitinib Meets Co-Primary End Points in Phase 3 Nonsegmental Vitiligo TrialsByKaitlyn Bader, Assistant Managing EditorJuly 30th 2026